Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study To Evaluate Methods To Evaluate Back Pain

21. februar 2013 oppdatert av: Wyeth is now a wholly owned subsidiary of Pfizer

A Pilot Study To Evaluate Various Methodologies For Assessing The Treatment Of Low Back Pain

The study is designed to assess methods used in clinical research.

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Faktiske)

61

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Forente stater
    • California
      • Loma Linda, California, Forente stater, 92350
        • Pfizer Investigational Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 55 år (Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Lower back pain
  • Male or female in generally good health, from 18 to 55 years of age (inclusive)

Exclusion Criteria:

  • Pregnant or lactating
  • Subject has evidence or history of radiculopathy, i.e. sciatica extending below the knee (numbness, tingling, or shooting pain), or other neurologic deficits (abnormal straight leg raise test, patellar reflexes, and/or bowel and bladder function);
  • Subject has a history of previous back surgery;
  • Subject has back pain resulting from traumatic injury involving physical evidence of bruising, swelling, or inflammation to the abdomen or low back area which occurred less than 48 hours prior to enrollment
  • Has taken an investigational drug within the past 30 days prior to entering the study, or currently enrolled in another investigational study
  • Is a member or relative of the study site staff, CRO or Sponsor organization directly involved with the study or had a household member or relative participate concurrently or previously in this study
  • Has previously been enrolled in this study

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: 1
Heat device
Enhet: Heat Device
8-Hour Heatwrap
Andre navn:
  • Heatwrap
Sham-komparator: 2
Placebo arm
Enhet: Sham Device
Inactive wrap worn for 8 hours
Aktiv komparator: 3
Marketed analgesic
Legemiddel: marketed analgesic
2 x 200 mg ibuprofen tablets
Placebo komparator: 4
(Oral) Placebo comparator
Legemiddel: Placebo
2 x placebo tablets

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Time to First Perceptible Relief (Confirmed by Meaningful Relief)
Tidsramme: Baseline (time of wrap application or oral treatment administration) up to 4 hours
"First perceptible relief" defined as the elapsed time from wrap application or oral treatment until the participant depressed the first stopwatch labeled "first perceptible relief" (any pain relieving effect), provided the participant also depressed the second stopwatch labeled "meaningful relief" (meaningful to participant) by the end of the scheduled in-patient evaluation (4 hours / 240 minutes). If the confirmation was not achieved, the participant was censored at the time when the first stopwatch was depressed. Confidence interval (CI) calculated using the method of Simon & Lee.
Baseline (time of wrap application or oral treatment administration) up to 4 hours

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Time to Meaningful Relief
Tidsramme: Baseline (time of wrap application or oral treatment administration) up to 4 hours
Time to "meaningful relief" defined as elapsed time from start of treatment until participant depressed the second stopwatch indicating "meaningful relief" (meaningful to participant). Participant consider censored if participant did not depress the stopwatch by end of 4-hour in-patient evaluation, or became a treatment failure (rescue or discontinuation) during the time prior to depressing the second stopwatch. Censoring was at time of dropout if participant withdrew for non-efficacy related reasons during the 4-hour in-patient portion of the study. CI calculated using method of Simon & Lee.
Baseline (time of wrap application or oral treatment administration) up to 4 hours
Time Weighted Sum of Pain Relief From 0 Through 8 Hours (TOTPAR 0-8)
Tidsramme: Baseline (time of wrap application or oral treatment administration) up to 8 hours
TOTPAR 0-8 sum of pain relief from 0 through 8 hours, weighted by the time duration between the current timepoint and the previous timepoint. Pain relief rated hourly (from baseline) by the participant on a 6-point scale: 0=no relief, 1=a little relief, 2=less than half relief, 3=more than half relief, 4=a lot of relief, 5=complete relief. Total possible score 0 to 40; higher score indicated better relief.
Baseline (time of wrap application or oral treatment administration) up to 8 hours
Time Weighted Sum of Change From Baseline in the Back Stiffness Score Over 8 Hours
Tidsramme: Baseline (time of wrap application or oral treatment administration) up to 8 hours
Time weighted sum of change calculated as sum of change from baseline in back stiffness scores from 0 through 8 hours, weighted by time duration between current timepoint and previous timepoint. Based on hourly (from baseline) back stiffness assessment rating from 0 (no muscle stiffness) to 100 (most possible muscle stiffness). Sum of change derived by subtracting score at post-dosing time point from baseline score. Total possible score -800 to 800; higher positive value was indicative of greater improvement.
Baseline (time of wrap application or oral treatment administration) up to 8 hours
Time to Treatment Failure
Tidsramme: Baseline (time of wrap application or oral treatment administration) up to 8 hours
Time to treatment failure defined as time from dosing to the time of rescue medication within the scheduled duration of the study (8 hours); or for participants who withdrew from the study due to lack of efficacy without taking rescue medication, the time of the last assessment was considered the time to treatment failure; or if participant did not take rescue medication, or did not discontinue due to lack of efficacy, the time to treatment failure was considered censored at 8 hours (the scheduled duration of the study).
Baseline (time of wrap application or oral treatment administration) up to 8 hours
Individual Time-Point Pain Relief Scores
Tidsramme: At 60, 120, 180, 240, 300, 360, 420, and 480 minutes
Pain relief rated hourly (from baseline) by the participant on a 6-point scale: 0=no relief, 1=a little relief, 2=less than half relief, 3=more than half relief, 4=a lot of relief, 5=complete relief.
At 60, 120, 180, 240, 300, 360, 420, and 480 minutes
Change From Baseline in Individual Time-point Back Stiffness Scores
Tidsramme: At 60, 120, 180, 240, 300, 360, 420, and 480 minutes
Low back muscle stiffness rated hourly (from baseline) by the participant by placing a line on a visual analog scale (VAS) from 0 millimeters (mm) to 100 mm in length with 0=no muscle stiffness up to 100 (most possible stiffness).
At 60, 120, 180, 240, 300, 360, 420, and 480 minutes
Change From Baseline (Bsl) in Combined Flexibility Score: Extension
Tidsramme: Baseline (time of wrap application or oral treatment administration) and 4 hours
Flexibility assessed using Paris Plinth table with maximum extension (as if performing a sit-up) of 20 degrees movement. Angle at Bsl and at 4 hours standardized to 100 for assessment of maximum angle (x degrees), x degrees minus 5, and x degrees plus 5. Flexibility score derived using standardized value and VAS score (participant rating of pain by marking level of pain on 100 mm line 0=no pain up to 100=worst pain). Final derived data for extension flexibility were average of the extension flexibility data on the combined score (range -66 to 552); higher value indicated greater improvement.
Baseline (time of wrap application or oral treatment administration) and 4 hours
Change From Baseline (Bsl) in Overall Combined Flexibility Score: Side-to-Side
Tidsramme: Baseline (time of wrap application or oral treatment administration) and 4 hours
Flexibility assessed using Paris Plinth table with maximum side-to-side movement of plus or minus (+/-) 10 degrees for left, and right (L, R), movement. Angle at Bsl and 4 hours standardized to 100 for assessment of maximum angle (x degrees), x degrees - 5, and x degrees + 5. Flexibility score derived using standardized value and VAS score (participant rating of level of pain on 100 mm line 0=no pain to 100=worst pain). Final derived data for overall flexibility was the average of side-to-side (L, R) flexibility data on the combined score (range -81 to 264); higher value=greater improvement.
Baseline (time of wrap application or oral treatment administration) and 4 hours
Change From Baseline (Bsl) in Overall Combined Flexibility Score: Rotation
Tidsramme: Baseline (time of wrap application or oral treatment administration) and 4 hours
Flexibility assessed using Paris Plinth table with maximum rotation at waist of plus or minus (+/-) 30 degrees for left, and right (L, R), movement. Angle at Bsl and at 4 hours standardized to 100 for assessment of maximum angle (x degrees), x degrees - 5, and x degrees + 5. Flexibility score derived using standardized value and VAS score (participant rating of level of pain on 100 mm line 0=no pain up to 100=worst pain). Final derived data for overall flexibility were the average of rotation (L, R) flexibility data on combined score (range -80 to 155); higher value=greater improvement.
Baseline (time of wrap application or oral treatment administration) and 4 hours
Change From Baseline in the Angle Measurement at Maximum Flexion for Flexibility Measures: Extension
Tidsramme: Baseline (time of wrap application or oral treatment administration) and 4 hours
Participant placed in a prone position on Paris Plinth table which is moved at 1 degree per second to maximum movement of 20 degrees for extension (as if performing a sit-up) to the degree of movement at which participant perceives discomfort or pain. Higher score indicated greater improvement.
Baseline (time of wrap application or oral treatment administration) and 4 hours
Change From Baseline in the Angle Measurement at Maximum Flexion for Flexibility Measures: Side-to-Side
Tidsramme: Baseline (time of wrap application or oral treatment administration) and 4 hours
Participant placed in a prone position on Paris Plinth table which is moved at 1 degree per second to maximum movement +/- 10 degrees for left, and right, side-to-side movement to the degree of movement at which participant perceives discomfort or pain. Maximum flexion based on the average of the left and right side-to-side scores. Higher score indicated greater improvement.
Baseline (time of wrap application or oral treatment administration) and 4 hours
Change From Baseline in the Angle Measurement at Maximum Flexion for Flexibility Measures: Rotation
Tidsramme: Baseline (time of wrap application or oral treatment administration) and 4 hours
Participant placed in a prone position on Paris Plinth table which is moved at 1 degree per second to maximum rotation at waist of +/- 30 degrees for left, and right, movement to the degree of movement at which participant perceives discomfort or pain. Maximum flexion based on the average of the left and right rotation scores. Higher score indicated greater improvement.
Baseline (time of wrap application or oral treatment administration) and 4 hours
Change From Baseline (Bsl) in Pain Measurement for Flexibility Measure: Extension
Tidsramme: Baseline (time of wrap application or oral treatment administration) and 4 hours
Flexibility assessed using Paris Plinth table with maximum extension of 20 degrees movement (as if performing a sit-up). When participant feels discomfort or pain, participant places a mark to rate discomfort/pain (maximum) on a VAS of 100 mm in length with 0=no discomfort/no pain up to 100=most discomfort/most pain. Movement decreased 5 degrees (minus) and discomfort rated on VAS. Movement increased 5 degrees (plus) beyond first point when pain was reported and discomfort/pain again rated on the VAS. Higher score indicated greater discomfort/pain.
Baseline (time of wrap application or oral treatment administration) and 4 hours
Change From Baseline in Pain Measurement for Flexibility Measure: Side-to-Side
Tidsramme: Baseline (time of wrap application or oral treatment administration) and 4 hours
Flexibility assessed using Paris Plinth table with maximum side-to-side movement of +/- 10 degrees for L, R movement. When participant feels discomfort or pain, participant places a mark to rate discomfort/pain (maximum) on a VAS of 100 mm in length with 0=no discomfort/no pain up to 100=most discomfort/most pain. Movement decreased 5 degrees (minus) and discomfort rated on VAS. Movement increased 5 degrees (plus) beyond first point when pain was reported and discomfort/pain again rated on the VAS. Analyses based on the average of L, R scores. Higher score indicated greater discomfort/pain.
Baseline (time of wrap application or oral treatment administration) and 4 hours
Change From Baseline in Pain Measurement for Flexibility Measure: Rotation
Tidsramme: Baseline (time of wrap application or oral treatment administration) and 4 hours
Flexibility assessed using Paris Plinth table with maximum rotation at waist of +/- 30 degrees for L, R movement. When participant feels discomfort or pain, participant places a mark to rate discomfort/pain (maximum) on a VAS of 100 mm in length with 0=no discomfort/no pain up to 100=most discomfort/most pain. Movement decreased 5 degrees (minus) and discomfort rated on VAS. Movement increased 5 degrees (plus) beyond first point when pain was reported and discomfort/pain again rated on the VAS. Analyses based on the average of L, R scores. Higher score indicated greater discomfort/pain.
Baseline (time of wrap application or oral treatment administration) and 4 hours
Number of Participants Per Categorical Score for Global Assessment of Study Treatment
Tidsramme: Baseline (time of wrap application or oral treatment administration) up to 8 hours
At hour 8, or at the time of rescue, if it occurred, participants performed a global assessment in their diary in response to the question: How would you rate the study treatment as a pain reliever? Very Poor=0, Poor=1, Fair=2, Good=3, Very Good=4, Excellent=5.
Baseline (time of wrap application or oral treatment administration) up to 8 hours

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Hjelpsomme linker

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. februar 2010

Primær fullføring (Faktiske)

1. juli 2010

Studiet fullført (Faktiske)

1. juli 2010

Datoer for studieregistrering

Først innsendt

8. januar 2010

Først innsendt som oppfylte QC-kriteriene

8. januar 2010

Først lagt ut (Anslag)

11. januar 2010

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

1. april 2013

Siste oppdatering sendt inn som oppfylte QC-kriteriene

21. februar 2013

Sist bekreftet

1. februar 2013

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • TC-09-20

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på Smerte

Kliniske studier på Heat Device

Søk i lignende forsøk

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

CROs by country

CROs in Thailand

Forhold

Sjeldne sykdommer

Legemiddelintervensjoner

Kosttilskudd

Sponsor / samarbeidspartnere

Steder

Abonnere